Arcus Biosciences, Inc. (NYSE:RCUS) announced that it has entered into a purchase agreement with returning investor Gilead Sciences, Inc. (NasdaqGS:GILD) for private placement of 5,650,000 shares at an issue price of $39 per share for gross proceeds of $220,350,000 on January 31, 2021. Post the closing, the investor's stake in the company will increase from approximately 13% to 19.5%. The transaction is subject to customary closing conditions.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.93 USD | -1.52% |
|
-5.19% | -20.63% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.63% | 1.38B | |
+23.13% | 46.93B | |
+37.01% | 39.08B | |
-8.73% | 38.48B | |
+28.09% | 31.01B | |
-12.26% | 26.14B | |
+10.57% | 25.88B | |
+32.23% | 12.53B | |
-6.56% | 11.36B | |
-12.56% | 10.65B |
- Stock Market
- Equities
- RCUS Stock
- News Arcus Biosciences, Inc.
- Arcus Biosciences, Inc. announced that it expects to receive $220.35 million in funding from Gilead Sciences, Inc.